Melissa joined Brandon Capital in 2018.
Dr Melissa Byrne has spent more than 15 years in the life sciences industry, with her expertise and experience spanning cardiovascular physiology, medical research, research translation, and commercialisation. Prior to joining Brandon Capital, Melissa held an academic position at Baker Heart Institute in Melbourne where she led formal pre-clinical research required for clinical development and conducted research and safety trials for the development of medical devices and therapeutics. These trials, including first-in-man studies that Melissa has completed and been involved in, have been pivotal for both the commercialisation and transfer of knowledge for a number of cardiovascular devices for use in the clinical setting. As a consequence, she has been a named inventor on four US patent filings.
A cardiovascular physiologist with commercial and academic experience, Melissa is passionate about taking research from the lab to the clinic.
Melissa was awarded a Guidant Industry Fellowship as part of an NIH Program Grant focused on improved targeting of patients for CRT therapy at Johns Hopkins Medicine, Baltimore, USA. She has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Cardiovascular Physiology from Monash University and a Graduate Certificate, Research Commercialisation from RMIT University.
She is a Director for Pathios Therapeutics Pty Ltd and Perx Health, Alternate Director for George Medicines and Scientific Advisor for Cadmus (GAICD).
